REPRIEVE
September 17, 2020
Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need […]
September 17, 2020
Background: The REPRIEVE Mechanistic Substudy (A5333s) represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, […]
September 3, 2020
The REPRIEVE study, which is primarily looking at a statin’s effect on cardiovascular disease, is shedding light on many other mysteries. Benjamin RyanEditor at Large, POZ […]
September 3, 2020
Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world. With 7,770 […]
July 22, 2020
The suite of manuscripts, utilizing key baseline data from the REPRIEVE trial, highlight the impact and prevalence of critical comorbidities among a global cohort of people […]
July 22, 2020
The impact and prevalence of heart disease and other critical comorbidities on an aging global population with human immunodeficiency virus (HIV) have emerged from a suite […]
April 24, 2017
Stemming from the INTREPID Trial, three recently published papers give credence to pitavastatin’s ability to lower cholesterol and dampen inflammation in people living with HIV.
December 1, 2015
Leadership from REPRIEVE: Randomized Trial to Prevent Vascular Events in HIV, would like to recognize World AIDS Day as a time to remember those we have lost to HIV/AIDS and also recognize the progress that has been made to help people with HIV live longer, healthier lives.
July 30, 2015
JAMA article highlights REPRIEVE trial for studying ways to prevent HIV-Related Heart Disease! Individuals living with HIV are at increased risk of heart disease.